Skip to main content

Advertisement

Table 3 Hazard ratios for bDMARD-free remission failure (multivariate analysis)

From: Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study

Factor HR (95% CI) p value
Type of bDMARD
 TNFi(mAb)/TNFi(R/P) 0.67 (0.42–1.08) 0.10
 TNFi(mAb)/CTLA4-Ig 1.04 (0.54–1.97) 0.91
 TNFi(mAb)/IL-6Ri 0.63 (0.40–0.99) 0.05
 CTLA4-Ig/TNFi(R/P) 0.65 (0.33–1.29) 0.22
 CTLA4-Ig/IL-6Ri 0.61 (0.31–1.18) 0.14
 TNFi(R/P)/IL-6Ri 0.93 (0.56–1.56) 0.79
Disease duration < 2 years /≥ 2 years 0.97 (0.65–1.44) 0.89
bDMARD-naïve, naïve/switch 0.85 (0.57–1.26) 0.42
Reason for discontinuation, remission/other reason 0.66 (0.38–1.14) 0.13
Boolean remission at the time of discontinuation, achieved/not achieved 0.63 (0.42–0.93) 0.02
Remission maintenance period before discontinuation, > 6 months/≥ 6 months 0.50 (0.32–0.78) 0.00
Methotrexate usage at the time of discontinuation, yes/no 1.10 (0.70–1.74) 0.67
Glucocorticoid usage at the time of discontinuation, yes/no 1.50 (1.05–2.15) 0.03
  1. Cox’s proportional hazard model used to determine factors associated with maintenance of bDMARD-free remission in multivariate analysis. Factors included in the analysis selected according to results of univariate analysis and clinical meaningfulness
  2. bDMARD biological disease-modifying antirheumatic drug, HR hazard ratio, CI confidence interval, TNFi(mAb) monoclonal antibodies against TNF (infliximab, adalimumab, and golimumab), TNFi(R/P) soluble TNF receptor or Fab fragments against TNF fused with polyethylene glycol (etanercept and certolizumab), CTLA4-Ig abatacept, IL-6Ri interleukin-6 receptor inhibitor (tocilizumab), TNF tumor necrosis factor